Doma Perpetual Capital Management LLC, a financial investment firm, has made a new investment in Afya Limited (NASDAQ:AFYA). The firm has acquired 294,909 shares of Afya Limited, valued at approximately $6,467,000. This investment now accounts for 6.4% of Doma Perpetual Capital Management LLC's portfolio, making it the 5th largest position. Other institutional investors and hedge funds have also made changes to their holdings of Afya Limited. Afya Limited is a medical education group in Brazil that provides educational products and services to medical learners.
Kent Lake Capital LLC, another financial investment firm, has sold the majority of its shares in Akoya Biosciences, Inc. (NASDAQ:AKYA) during the fourth quarter. The company reduced its holdings by 84.3%, selling 629,686 shares and leaving them with 116,835 shares worth $570,000. Other institutional investors have also made changes to their holdings of the company. Nisa Investment Advisors LLC increased its stake in Akoya Biosciences by 10,169.5% in the fourth quarter, now owning 6,059 shares of the company's stock worth $30,000. UBS Group AG also lifted its stake in Akoya Biosciences by 154.9% in the first quarter, now owning 4,158 shares worth $34,000. Lazard Asset Management LLC acquired a new stake in Akoya Biosciences in the fourth quarter, valued at approximately $36,000. Barclays PLC increased its holdings in Akoya Biosciences by 533.0% in the fourth quarter, now owning 4,235 shares valued at $40,000. Additionally, Citigroup Inc. acquired a new stake in Akoya Biosciences in the second quarter, valued at about $40,000. Institutional investors and hedge funds now own 79.42% of the company's stock.
Epoch Investment Partners Inc., another institutional investor, has also reduced its stake in Malibu Boats, Inc. (NASDAQ:MBUU) by 11.3% in the fourth quarter. The company now owns 237,089 shares of Malibu Boats' stock after selling 30,079 shares during the quarter. Other institutional investors have also modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in Malibu Boats during the fourth quarter worth about $48,000. Benjamin Edwards Inc. raised its position in shares of Malibu Boats by 13.8% during the fourth quarter, now owning 2,618 shares valued at $144,000. Andina Capital Management LLC purchased a new position in Malibu Boats in the fourth quarter worth approximately $225,000. Hsbc Holdings PLC acquired a new stake in Malibu Boats during the third quarter worth $203,000. Finally, Howe & Rusling Inc. increased its stake in Malibu Boats by 14.7% during the third quarter, now owning 4,427 shares valued at $217,000. Hedge funds and other institutional investors now own 91.35% of the company's stock.
Perceptive Advisors LLC, a hedge fund, has increased its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) by 76.9% in the fourth quarter. The firm now owns 2,003,058 shares of Cabaletta Bio, Inc., valued at $45,469,000. Several other hedge funds have also made changes to their positions in Cabaletta Bio. Cabaletta Bio's stock is currently down 15.1%. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48). Nine research analysts have rated the stock with a buy rating, and the consensus target price is $34.33. Cabaletta Bio is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune diseases.
Several brokerages have recently provided their ratings and price targets for Akoya Biosciences. Canaccord Genuity Group reiterated a 'buy' rating and set a price target of $10.00 on the company's shares. JPMorgan Chase & Co. lowered their price target from $12.00 to $10.00 and assigned an 'overweight' rating to the company. UBS Group raised their price target on Akoya Biosciences from $7.00 to $7.50 and gave the company a 'buy' rating. Guggenheim initiated coverage on Akoya Biosciences with a 'neutral' rating. Overall, the company has an average rating of 'Moderate Buy' and an average price target of $9.07.